52678-40-7

Usage

Uses

Used in Pharmaceutical Research and Development:
2,6-Dichloro-9-[2,3-O-(1-Methylethylidene)-Beta-D-ribofuranosyl]-9H-purine serves as a key compound in pharmaceutical research and development, specifically for the study and creation of new drugs targeting purine nucleosides and nucleotides. Its unique molecular structure allows it to interact with biological systems in ways that can be harnessed for therapeutic purposes.
Used in Biochemical Studies:
In the field of biochemistry, 2,6-Dichloro-9-[2,3-O-(1-Methylethylidene)-Beta-D-ribofuranosyl]-9H-purine is utilized as a research tool to explore the mechanisms of action and interactions involving purine-based molecules. This can lead to a better understanding of various biological processes and the development of targeted therapies.
Used in Chemical Synthesis:
2,6-Dichloro-9-[2,3-O-(1-Methylethylidene)-Beta-D-ribofuranosyl]-9H-purine is also employed as an intermediate in the synthesis of other complex organic compounds, particularly those with potential applications in medicine and biology. Its unique functional groups make it a valuable building block for creating novel molecules with specific biological activities.
Used in Diagnostic Applications:
2,6-Dichloro-9-[2,3-O-(1-Methylethylidene)-Beta-D-ribofuranosyl]-9H-purine may find use in diagnostic applications, where its interactions with certain biological targets can be exploited to develop assays or tests for detecting diseases or monitoring biological processes related to purine metabolism.
Note: The specific uses mentioned above are inferred based on the compound's structure and potential relevance to purine nucleosides and nucleotides. The actual applications may vary and would require further research and validation.

Upstream product

• 67-64-1 acetone 
• 13276-52-3 2,6-dichloropurine riboside 
• 77-76-9 2,2-dimethoxy-propane 

Relevant academic research and scientific papers

Silicon(IV) phthalocyanines substituted axially with different nucleoside moieties. Effects of nucleoside type on the photosensitizing efficiencies and in vitro photodynamic activities

A series of new silicon(IV) phthalocyanines (SiPcs) di-substituted axially with different nucleoside moieties have been synthesized and evaluated for their singlet oxygen quantum yields (ΦΔ) and in vitro photodynamic activities. The adenosine-substituted SiPc shows a lower photosensitizing efficiency (ΦΔ = 0.35) than the uridine- and cytidine-substituted analogs (ΦΔ = 0.42-0.44), while the guanosine-substituted SiPc exhibits a weakest singlet oxygen generation efficiency with a ΦΔ value down to 0.03. On the other hand, replacing axial adenosines with chloro-modified adenosines and purines can result in the increase of photogenerating singlet oxygen efficiencies of SiPcs. The formed SiPcs 1 and 2, which contain monochloro-modified adenosines and dichloro-modified purines respectively, appear as efficient photosensitizers with ΦΔ of 0.42-0.44. Both compounds 1 and 2 present high photocytotoxicities against HepG2 and BGC823 cancer cells with IC50 values ranging from 9 nM to 33 nM. The photocytotoxicities of these two compounds are remarkably higher than the well-known anticancer photosensitizer, chlorin e6 (IC50 = 752 nM against HepG2 cells) in the same condition. As revealed by confocal microscopy, for both cell lines, compound 1 can essentially bind to mitochondria, while compound 2 is just partially localized in mitochondria. In addition, the two compounds induce cell death of HepG2 cells likely through apoptosis.

PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER

Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.